Maytansinoid

By Targets:	ADC Antibody (1) ADC Cytotoxin (6) Antibody-Drug Conjugates (ADCs) (2) Carbonic Anhydrase (1) CCR (1) Checkpoint Kinase (Chk) (1) CXCR (1) Drug Metabolite (3) Drug-Linker Conjugates for ADC (3) Isotope-Labeled Compounds (3) Microtubule/Tubulin (5) STAT (1)
By Research Areas:	Cancer (14)
Click Chemistry:	DBCO (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148870

Maytansinoid B	ADC Cytotoxin	Cancer
Maytansinoid B is a kind of ADC Cytotoxin. Maytansinoid B can be used to conjugates with antibodies to form antibody-drug conjugates (ADCs). Maytansinoids are known as antimitotic agents, binding to tubulin and inhibiting microtubule assembly. Maytansinoids induces G2/M arrest in the cell cycle to induce apoptosis .

HY-130080

DM3 Maytansinoid DM3	ADC Cytotoxin Microtubule/Tubulin	Cancer
DM3 (Maytansinoid DM3) is a maytansine analog bearing disulfide or thiol groups and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs) .

HY-143985S

Maytansinoid DM4 impurity 5-d6

Drug Metabolite Isotope-Labeled Compounds Others

Maytansinoid DM4 impurity 5-d₆ is the deuterium labeled Maytansinoid DM4 impurity 5[1].
HY-143992S

Maytansinoid DM4 impurity 2-d6

Drug Metabolite Isotope-Labeled Compounds Others

Maytansinoid DM4 impurity 2-d₆ is the deuterium labeled Maytansinoid DM4 impurity 2[1].
HY-143993S

Maytansinoid DM4 impurity 3-d6

Drug Metabolite Isotope-Labeled Compounds Others

Maytansinoid DM4 impurity 3-d₆ is the deuterium labeled Maytansinoid DM4 impurity 3[1].

Maytansinoid DM4 impurity 5-d6	Drug Metabolite Isotope-Labeled Compounds	Others
Maytansinoid DM4 impurity 5-d₆ is the deuterium labeled Maytansinoid DM4 impurity 5[1].

Maytansinoid DM4 impurity 2-d6	Drug Metabolite Isotope-Labeled Compounds	Others
Maytansinoid DM4 impurity 2-d₆ is the deuterium labeled Maytansinoid DM4 impurity 2[1].

Maytansinoid DM4 impurity 3-d6	Drug Metabolite Isotope-Labeled Compounds	Others
Maytansinoid DM4 impurity 3-d₆ is the deuterium labeled Maytansinoid DM4 impurity 3[1].

HY-19792

Mertansine 15+ Cited Publications DM1; Maytansinoid DM1	Microtubule/Tubulin ADC Cytotoxin	Cancer
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-151559

*Zn-DPA-maytansinoid* conjugate 1**	Checkpoint Kinase (Chk) STAT CXCR CCR	Cancer
Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. Zn-DPA-maytansinoid conjugate 1 induces lasting regression of tumor growth and rejuvenates tumor microenvironment (TME) to an “inflamed hot tumor” .

HY-P990027

Izeltabart	ADC Antibody	Cancer
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .

HY-W074975

CL 5343 5-Amino-1,3,4-thiadiazole-2-sulfonamide	Carbonic Anhydrase	Cancer
CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is an inhibitor of human carbonic anhydrase B (HCA-B). CL 5343 can serve as a CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-136261

DM1-PEG4-DBCO	Drug-Linker Conjugates for ADC	Cancer
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-100128

DM1-SMe	Microtubule/Tubulin ADC Cytotoxin	Cancer
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent agent Maytansine, with IC₅₀s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines .

HY-148528

SC-VC-PAB-N-Me-L-Ala-Maytansinol	Others	Cancer
SC-VC-PAB-N-Me-L-Ala-Maytansinol (compound B1) can be used to synthesis MCC-Maytansinoid A. SC-VC-PAB-N-Me-L-Ala-Maytansinol can be used as a control compound for the cancer research .

HY-148818

S-Me-DM4 1 Publications Verification	ADC Cytotoxin	Others
S-Me-DM4 is a metabolite of DM4 S-methylated by intracellular enzyme. DM4 (HY-100503) is a microtubule-depolymerizing maytansinoid with strong cytotoxicity. DM4 can be used as an ADC Cytotoxin molecule .

HY-145663

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM	Drug-Linker Conjugates for ADC	Cancer
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety .

HY-132258A

Mirvetuximab soravtansine (solution) IMGN853 (solution)	Antibody-Drug Conjugates (ADCs)	Cancer
Mirvetuximab soravtansine (IMGN853) solution is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .

HY-100504

S-methyl DM1	Microtubule/Tubulin ADC Cytotoxin	Cancer
S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a K_d of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects .

HY-136260

DBCO-PEG4-Ahx-DM1	Drug-Linker Conjugates for ADC	Cancer
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library	94 compounds
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide. The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 94 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Toxins for Antibody-Drug Conjugate Research Library

94 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 94 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Target	Research Area

HY-P990027

Izeltabart	ADC Antibody	Cancer
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

Cat. No.	Product Name	Chemical Structure

HY-143985S

Maytansinoid DM4 impurity 5-d6

Maytansinoid DM4 impurity 5-d₆ is the deuterium labeled Maytansinoid DM4 impurity 5[1].
HY-143992S

Maytansinoid DM4 impurity 2-d6

Maytansinoid DM4 impurity 2-d₆ is the deuterium labeled Maytansinoid DM4 impurity 2[1].
HY-143993S

Maytansinoid DM4 impurity 3-d6

Maytansinoid DM4 impurity 3-d₆ is the deuterium labeled Maytansinoid DM4 impurity 3[1].

Maytansinoid DM4 impurity 5-d6
Maytansinoid DM4 impurity 5-d₆ is the deuterium labeled Maytansinoid DM4 impurity 5[1].

Maytansinoid DM4 impurity 2-d6
Maytansinoid DM4 impurity 2-d₆ is the deuterium labeled Maytansinoid DM4 impurity 2[1].

Maytansinoid DM4 impurity 3-d6
Maytansinoid DM4 impurity 3-d₆ is the deuterium labeled Maytansinoid DM4 impurity 3[1].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81055

	DM1 Antibody (YA898) Mertansine, Maytansinoid DM1, DM 1, 139504-50-0	ELISA
	DM1 Antibody (YA898) is an unconjugated, mouse-derived, anti-DM1 (YA898) monoclonal antibody. DM1 Antibody (YA898) can be used for: ELISA, Sandwich ELISA, Competitive ELISA expriments in background without labeling.


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-136261

DM1-PEG4-DBCO		DBCO
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136260

DBCO-PEG4-Ahx-DM1		DBCO
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Name
Email *

	Sorry, but the email address you supplied was invalid.